Alan L Ho, MD, PhD
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alan L Ho, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:57 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04544111 · PDR001 Combination Therapy for Radioiodine-Refractory Thyroid CancerMemorial Sloan Kettering Cancer Center · active not recruiting · Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer · principal investigator
- Ph1NCT04462471 · Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid CancersMemorial Sloan Kettering Cancer Center · completed · Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular · principal investigator
- Early Ph1NCT02145143 · Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot StudyMemorial Sloan Kettering Cancer Center · completed · Thyroid Carcinoma · principal investigator
- Ph2NCT01558661 · Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic CarcinomaMemorial Sloan Kettering Cancer Center · completed · Adenoid Cystic Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.